FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

[FierceBiotech @FierceBiotech]

Bain-backed bone specialist Angitia drops lead spinal fusion candidate https://t.co/Zti4osSsAj

[FierceBiotech @FierceBiotech]

Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer’s asset in $2.2B deal https://t.co/s8luSibnIr

[FierceBiotech @FierceBiotech]

Ipsen is on a roll this week, scooping up its second biotech in three days to firm up its pipeline with promising clinical-stage candidates. https://t.co/w5Np8QuBKb

[FierceBiotech @FierceBiotech]

Abivax rebounds from stock drop with safety data for much-hyped colitis prospect https://t.co/Wsdw1Ox7zi

[FierceBiotech @FierceBiotech]

FDA gene therapy regulator Vijay Kumar steps down from leadership role https://t.co/AgZLSwkjji

[FierceBiotech @FierceBiotech]

Praxis faces FDA decision delay as analysts point finger at agency layoffs https://t.co/FJVA6m7jl4

[FierceBiotech @FierceBiotech]

Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive. https://t.co/VqZbFmBEFH

[FierceBiotech @FierceBiotech]

Deerfield’s Boulevard Bio pens $1.6B deal for trispecific TCE from China’s Metis TechBio https://t.co/HkR75d09Nz

[FierceBiotech @FierceBiotech]

Vistagen’s social anxiety disorder drug candidate has flunked another phase 3 trial. But with a post hoc subpopulation analysis linking fasedienol to a nominal statistically significant improvement, the biotech plans to talk to the FDA about a path to approval based on a single future pivotal study. https://t.co/3gVZJnVXNF

[FierceBiotech @FierceBiotech]

China approved the first solid tumor CAR-T. Will the US follow? https://t.co/FI4qBJfPds

[FierceBiotech @FierceBiotech]

BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships https://t.co/JAgV9bLeVs

[FierceBiotech @FierceBiotech]

UK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors https://t.co/57yAmIPxMn

[FierceBiotech @FierceBiotech]

AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor https://t.co/BQrRXHSjoO

[FierceBiotech @FierceBiotech]

Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset https://t.co/dGcSNhCvdz

[FierceBiotech @FierceBiotech]

Evommune’s phase 2b trial flops, ending challenge to Novartis in hives https://t.co/suvnarLGzB

[FierceBiotech @FierceBiotech]

Ipsen is paying $450 million upfront to buy Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment. https://t.co/NsGv7nkaQB

[FierceBiotech @FierceBiotech]

Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect https://t.co/jMjEddPAkM

[FierceBiotech @FierceBiotech]

With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform https://t.co/SQdTtW0By7

[FierceBiotech @FierceBiotech]

A phase 3b trial of Otsuka’s ADHD prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch of the therapy. https://t.co/Yxestwi4Cf

[FierceBiotech @FierceBiotech]

How a gut feeling transformed cancer treatment forever https://t.co/BtCT940xnr #BIO2026